Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology
company developing botulinum toxin products for use in aesthetic
and therapeutic indications, today announced presentations of
clinical data for DaxibotulinumtoxinA Injectable (RT002) at TOXINS
2017, the Third International Neurotoxin Association Conference,
taking place at the Meliá Castilla Hotel in Madrid, Spain, January
18-21, 2017.
"The TOXINS conference gives us a unique opportunity to showcase
RT002 injectable in both aesthetic and therapeutic applications for
a scientific and clinical audience from around the world
specifically focused on the use of neurotoxins," said Dan Browne,
President and Chief Executive Officer at Revance. “These
presentations highlight the safety, efficacy and duration-of-effect
results for RT002 injectable from prior studies in both low and
high dose indications. We are excited by the prospects of
developing a next-generation neurotoxin with an improved safety
profile, enhanced treatment effectiveness and long duration,
whether for facial aesthetics, acute conditions or chronic disease
states. We look forward to reporting results from four ongoing
RT002 clinical trials in 2017, including the two SAKURA Phase 3
pivotal trials in glabellar lines, the final results for the Phase
2 trial in cervical dystonia and topline results from a Phase 2
trial for plantar fasciitis."
The scheduled data presentation titles and times at TOXINS 2017
are as follows:
Podium Presentation: “A New Botulinum Toxin Type A for the
Treatment of Glabellar Lines” Thursday, January 19, 5:30 pm,
Clinical Workshops 1A & 1B – Tapices Room
Steve Yoelin, MD, Ophthalmologist at Steve Yoelin MD Medical
Associates, will present final data from the company’s BELMONT
Phase 2 placebo and active controlled study of RT002 injectable for
the treatment of moderate to severe glabellar (frown) lines in
adults.
Poster Abstract: “Safety and Duration of Severity Reduction
in Glabellar Lines following an Injection of DaxibotulinumtoxinA:
Results of the BELMONT Study” Thursday, January 19 and
Friday, January 20, 12:00 – 2:30 pm – Patio Areas
Along with the podium presentation on the BELMONT Phase 2 data,
a poster was accepted, authored by: Jean D. Carruthers, MD,
Clinical Professor, at University of British Columbia, and Medical
Director at Jean Carruthers Cosmetic Surgery Inc.; Steve Yoelin,
MD, Ophthalmologist at Steve Yoelin MD Medical Associates; Carol Y.
Chung, Sr. Director, Biometrics and Data Management at Revance
Therapeutics, Inc., and Roman G. Rubio, Senior Vice President of
Clinical Development at Revance Therapeutics, Inc.
Podium Presentation: “A Phase 2, Open-Label, Dose-Escalating
Study to Evaluate the Safety and Preliminary Efficacy of
DaxibotulinumtoxinA Injectable (RT002) in Isolated Cervical
Dystonia” Friday, January 20, 2017, 3:00 pm, Clinical Tracks
1A & 1B – Castilla Room
Cynthia L. Comella, MD, Professor in the Department of
Neurological Sciences at Rush University Medical Center, Chicago,
Illinois, will present interim findings from the company’s U.S.
Phase 2 open-label, dose-escalating clinical study of
DaxibotulinumtoxinA Injectable (RT002) to treat moderate-to-severe
isolated cervical dystonia in adults.
About Revance Therapeutics, Inc.
Revance, a Silicon Valley-based biotechnology company, is
committed to the advancement of remarkable science. The company is
developing a portfolio of products for aesthetic medicine and
underserved therapeutic specialties, including dermatology,
orthopedics and neurology. Revance’s science is based upon a
proprietary peptide technology, which when combined with active
drug molecules, may help address current unmet needs.
Revance’s initial focus is on developing DaxibotulinumtoxinA,
the company’s highly purified botulinum toxin, for a broad spectrum
of aesthetic and therapeutic indications, including facial wrinkles
and muscle movement disorders. The company’s lead drug candidate,
DaxibotulinumtoxinA for Injection (RT002), is currently in
development for the treatment of glabellar lines, cervical dystonia
and plantar fasciitis with the potential to be the first
long-acting neurotoxin. The company holds worldwide rights for all
indications of RT002 injectable and RT001 topical and the
pharmaceutical uses of its proprietary peptide technology platform.
More information on Revance may be found
at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered
trademarks of Revance Therapeutics, Inc.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements related to the process and timing of, and
ability to complete, current and anticipated future clinical
development of our investigational drug product candidates,
including but not limited to initiation and design of clinical
studies for current and future indications, related results and
reporting of such results; statements about our business strategy,
timeline and other goals and market for our anticipated products,
plans and prospects; and statements about our ability to obtain
regulatory approval; and potential benefits of our drug product
candidates and our technologies.
Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from our expectations. These risks and uncertainties include, but
are not limited to: the outcome, cost, and timing of our product
development activities and clinical trials; the uncertain clinical
development process, including the risks that interim results are
not indicative of final results and that clinical trials may not
have an effective design or generate positive results; our ability
to obtain and maintain regulatory approval of our drug product
candidates; our ability to obtain funding for our operations; our
plans to research, develop, and commercialize our drug product
candidates; our ability to achieve market acceptance of our drug
product candidates; unanticipated costs or delays in research,
development, and commercialization efforts; the applicability of
clinical study results to actual outcomes; the size and growth
potential of the markets for our drug product candidates; our
ability to successfully commercialize our drug product candidates
and the timing of commercialization activities; the rate and degree
of market acceptance of our drug product candidates; our ability to
develop sales and marketing capabilities; the accuracy of our
estimates regarding expenses, future revenues, capital requirements
and needs for financing; our ability to continue obtaining and
maintaining intellectual property protection for our drug product
candidates; and other risks. Detailed information regarding factors
that may cause actual results to differ materially from the results
expressed or implied by statements in this press release may be
found in Revance's periodic filings with the Securities and
Exchange Commission (the "SEC"), including factors described in the
section entitled "Risk Factors" of our quarterly report on Form
10-Q filed November 4, 2016. These forward-looking statements speak
only as of the date hereof. Revance disclaims any obligation to
update these forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170118006293/en/
Investors:Revance Therapeutics, Inc.Jeanie Herbert,
714-325-3584jherbert@revance.comorBurns McClellanAmi Bavishi,
212-213-0006abavishi@burnsmc.comorTrade Media:Nadine Tosk,
504-453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024